Annual Drug Patent Expirations for EPCLUSA
Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. It is available from one supplier. There are twenty-six patents protecting this drug.
Drug patent litigation for EPCLUSA.
This drug has four hundred and twenty-two patent family members in forty-seven countries.
The generic ingredient in EPCLUSA is sofosbuvir; velpatasvir. One supplier is listed for this compound. Additional details are available on the sofosbuvir; velpatasvir profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
